IDEXX Laboratories, Inc. $IDXX Stock: VIRGINIA RETIREMENT SYSTEMS ET Al Grows Holdings

VIRGINIA RETIREMENT SYSTEMS ET Al increased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 36.8% during the third quarter, HoldingsChannel reports. The institutional investor owned 126,164 shares of the company’s stock after acquiring an additional 33,946 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in IDEXX Laboratories were worth $65,882,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp bought a new stake in IDEXX Laboratories in the second quarter worth approximately $628,223,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of IDEXX Laboratories by 4.6% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 911,489 shares of the company’s stock worth $479,844,000 after purchasing an additional 39,700 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its stake in shares of IDEXX Laboratories by 52.4% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company’s stock worth $471,335,000 after purchasing an additional 288,471 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of IDEXX Laboratories by 4.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 573,332 shares of the company’s stock valued at $322,145,000 after purchasing an additional 23,582 shares in the last quarter. Finally, Alyeska Investment Group L.P. raised its holdings in shares of IDEXX Laboratories by 97.3% during the 2nd quarter. Alyeska Investment Group L.P. now owns 401,082 shares of the company’s stock valued at $211,146,000 after purchasing an additional 197,808 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

Insiders Place Their Bets

In related news, Director Lawrence D. Kingsley sold 2,203 shares of the business’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the transaction, the director directly owned 9,568 shares in the company, valued at $5,090,941.44. The trade was a 18.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.79% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have weighed in on IDXX shares. KeyCorp started coverage on IDEXX Laboratories in a report on Monday, October 12th. They set a “sector weight” rating on the stock. Leerink Partners decreased their price target on IDEXX Laboratories from $725.00 to $715.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. Barclays lowered their price objective on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. Finally, Jefferies Financial Group cut their price objective on IDEXX Laboratories from $795.00 to $705.00 and set a “buy” rating on the stock in a research note on Tuesday, October 20th. Eight research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $721.67.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $551.21 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. The firm has a market capitalization of $43.42 billion, a price-to-earnings ratio of 38.76 and a beta of 1.55. The company’s fifty day moving average is $534.27 and its two-hundred day moving average is $574.09. IDEXX Laboratories, Inc. has a 52-week low of $500.61 and a 52-week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.94 by $0.33. The company had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The business’s revenue was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Equities research analysts forecast that IDEXX Laboratories, Inc. will post 14.81 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.